NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Vaccine Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



ImmunoCellular Therapeutics, Ltd.



ImmunoCellular Therapeutics Announces Ability to Characterize Distinct Antigens between Cancers Using Monoclonal Antibody Technology



June 11th, 2008

ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, announced that preclinical in vitro data related to the characterization of the target associated with its lead monoclonal antibody (ICT-109) will be presented at ASCO. The abstract (#14023) titled "Differential glycan profile of CEACAM5 expressed by small cell lung carcinoma (SCLC) in comparison with colorectal carcinoma," demonstrated dramatic disparities between the sugar patterns of CEACAM5 on these two cancer types, potentially enabling the development of discerning therapeutics thereby allowing greater safety and efficacy. Furthermore, monoclonal antibody ICT-109 demonstrated the ability to bind to the...


Source: Vaccine Weekly (2008-06-11)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login